期刊
BRITISH JOURNAL OF HAEMATOLOGY
卷 198, 期 3, 页码 482-491出版社
WILEY
DOI: 10.1111/bjh.18161
关键词
diffuse large B-cell lymphoma; obinutuzumab; pixantrone; relapse treatment
类别
资金
- CTI Biopharma
- Roche Pharma AG
- Roche
The combination of pixantrone with obinutuzumab showed clinical activity in patients with relapsed or refractory DLBCL, with an overall response rate of 35.3%. Median progression-free survival was 2.8 months and overall survival was 8 months. Patients with non-GCB phenotype had a superior outcome.
The prognosis of patients with relapsed diffuse large B-cell lymphoma (DLBCL) remains poor with current options. Here we prospectively evaluated the combination of pixantrone with obinutuzumab for up to six cycles for patients with relapsed or refractory DLBCL. Overall response rate (ORR) was the primary end-point. Sixty-eight patients were evaluated, median age was 75 years, median number of prior lines was three (range 1-10), 52 patients (76.5%) were diagnosed with DLBCL and 16 (23.5%) patients had transformed indolent lymphoma or follicular lymphoma (FL) IIIB. ORR was 35.3% for all and 40% for evaluable patients (16.6% complete response), median progression-free survival (PFS) and overall survival (OS) were 2.8 months and 8 months, respectively. Analysis of the cell of origin revealed a superior course for patients with non-GCB (germinal centre B-cell-like) phenotype [median OS not reached (n.r.) vs 5.2 months]. Patients with one prior line had an improved outcome over patients treated in later lines (PFS n.r. vs 2.5 months). Disease progression was the main reason for premature termination. Adverse events were mainly haematologic. The combination treatment revealed no unexpected adverse events. Most relevant non-haematologic toxicity was infection in 28% of patients. In summary, pixantrone-obinutuzumab showed clinical activity with sometimes long-term remission; however, the trial failed to meet its primary end-point.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据